In vivo, PTPN2 deletion results in increased anti-tumor immunity, with Ptpn2 deficient CD8+ T cells displaying better cytotoxic activity and reduced exhaustion compared to wildtype cells (58). The gene discussed is CD8A; the disease is neoplasm.